Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04493164
Title CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center

myeloproliferative neoplasm

acute myeloid leukemia

myelodysplastic syndrome


CPX-351 + Ivosidenib


Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST